282 related articles for article (PubMed ID: 32078492)
1. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine.
Brunet N; Moore DT; Lendvai Wischik D; Mattocks KM; Rosen MI
Subst Abus; 2022; 43(1):39-46. PubMed ID: 32078492
[No Abstract] [Full Text] [Related]
2. Advancing pharmacological treatments for opioid use disorder (ADaPT-OUD): protocol for testing a novel strategy to improve implementation of medication-assisted treatment for veterans with opioid use disorders in low-performing facilities.
Hagedorn H; Kenny M; Gordon AJ; Ackland PE; Noorbaloochi S; Yu W; Harris AHS
Addict Sci Clin Pract; 2018 Dec; 13(1):25. PubMed ID: 30545409
[TBL] [Abstract][Full Text] [Related]
3. Health center implementation of telemedicine for opioid use disorders: A qualitative assessment of adopters and nonadopters.
Uscher-Pines L; Raja P; Mehrotra A; Huskamp HA
J Subst Abuse Treat; 2020 Aug; 115():108037. PubMed ID: 32600625
[TBL] [Abstract][Full Text] [Related]
4. Comparing telemedicine to in-person buprenorphine treatment in U.S. veterans with opioid use disorder.
Lin LA; Fortney JC; Bohnert ASB; Coughlin LN; Zhang L; Piette JD
J Subst Abuse Treat; 2022 Feb; 133():108492. PubMed ID: 34175175
[TBL] [Abstract][Full Text] [Related]
5. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
[TBL] [Abstract][Full Text] [Related]
6. Fluctuations in barriers to medication treatment for opioid use disorder prescribing over the course of a one-year external facilitation intervention.
Gustavson AM; Kenny ME; Wisdom JP; Salameh HA; Ackland PE; Gordon AJ; Hagedorn HJ
Addict Sci Clin Pract; 2021 Aug; 16(1):51. PubMed ID: 34362445
[TBL] [Abstract][Full Text] [Related]
7. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
Speight C; Caiola C; Tyndall DE; Scott ES
J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
[TBL] [Abstract][Full Text] [Related]
8. The intertwined expansion of telehealth and buprenorphine access from a prescriber hub.
Moore DT; Wischik DL; Lazar CM; Vassallo GG; Rosen MI
Prev Med; 2021 Nov; 152(Pt 2):106603. PubMed ID: 33974959
[TBL] [Abstract][Full Text] [Related]
9. Implementation of Telemedicine Delivery of Medications for Opioid Use Disorder in Pennsylvania Treatment Programs During COVID-19.
Poulsen MN; Santoro W; Scotti R; Henderson C; Ruddy M; Colistra A
J Addict Med; 2023 Mar-Apr 01; 17(2):e110-e118. PubMed ID: 36129690
[TBL] [Abstract][Full Text] [Related]
10. A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.
Nyaku AN; Zerbo EA; Chen C; Milano N; Johnston B; Chadwick R; Marcello S; Baston K; Haroz R; Crystal S
BMC Health Serv Res; 2024 Feb; 24(1):179. PubMed ID: 38331802
[TBL] [Abstract][Full Text] [Related]
11. Perspectives of Patients Receiving Telemedicine Services for Opioid Use Disorder Treatment: A Qualitative Analysis of User Experiences.
Sousa JL; Raja P; Huskamp HA; Mehrotra A; Busch AB; Barnett ML; Uscher-Pines L
J Addict Med; 2022 Nov-Dec 01; 16(6):702-708. PubMed ID: 35861337
[TBL] [Abstract][Full Text] [Related]
12. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
[TBL] [Abstract][Full Text] [Related]
13. Preliminary results of the evaluation of the California Hub and Spoke Program.
Darfler K; Sandoval J; Pearce Antonini V; Urada D
J Subst Abuse Treat; 2020 Jan; 108():26-32. PubMed ID: 31400985
[TBL] [Abstract][Full Text] [Related]
14. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
15. Association of MOUD ECHO Participation on Expansion of Buprenorphine Prescribing in Rural Primary Care.
Salvador JG; Myers OB; Bhatt SR; Jacobsohn V; Lindsey L; Alkhafaji RS; Rishel Brakey H; Sussman AL
Subst Abus; 2023 Oct; 44(4):282-291. PubMed ID: 37902036
[TBL] [Abstract][Full Text] [Related]
16. System-level factors shaping the implementation of "hub and spoke" systems to expand MOUD in rural areas.
Snell-Rood C; Willging C; Showalter D; Peters H; Pollini RA
Subst Abus; 2021; 42(4):716-725. PubMed ID: 33284083
[No Abstract] [Full Text] [Related]
17. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
18. Stakeholder perspectives on a telemedicine referral and coordination model to expand medication treatment for opioid use disorder in rural primary care clinics.
Ober AJ; Dopp AR; Clingan SE; Curtis ME; Lin C; Calhoun S; Larkins S; Black M; Hanano M; Osterhage KP; Baldwin LM; Saxon AJ; Hichborn EG; Marsch LA; Mooney LJ; Hser YI
J Subst Use Addict Treat; 2024 Jan; 156():209194. PubMed ID: 37863356
[TBL] [Abstract][Full Text] [Related]
19. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
[TBL] [Abstract][Full Text] [Related]
20. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
